(R)-(+)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8OH-DPAT; Sigma, USA), a specific 5-HT1A receptor full agonist, L-368,899 hydrochloride (Tocris, UK), an OXT receptor antagonist, or OXT (Sigma, USA) was dissolved in saline and subcutaneously injected to pups (8OH-DPAT, 0.5 mg/kg; L-368,899, 3 mg/kg; OXT 83 I.U. [0.2–0.26 mg]/kg) every day from PD7 to PD21.
The treatment doses of 8OH-DPAT35 (link), L-368,89936 (link),37 (link) and OXT30 (link) were determined based on previous reports. The treatment duration of each drug was determined based on our previous reports5 (link). After weaning at PD21, the mice were divided into groups of two to five mice per cage. Saline was used as a control.
Free full text: Click here